RxSight, Inc.

RxSight, Inc. and Alcon have announced a non-exclusive collaboration to jointly develop adjustable presbyopia-correcting intraocular lenses (PCIOLs). Under the agreement, RxSight will receive a $60 million upfront payment and could earn up to an additional $140 million in milestone payments. The partnership aims to combine RxSight's post-operative light-adjustable technology with Alcon's PCIOL optical designs to enable fine-tuning of visual outcomes after cataract surgery. Alcon will handle global commercialization, while RxSight will manage development and manufacturing and receive royalties on net sales.

RxSight, Inc. announced preliminary financial results for the second quarter of 2026, expecting total revenue of $32-34 million, including $5-7 million from the Alcon strategic collaboration. The company also updated its full-year 2026 guidance, lowering sales expectations to $110-120 million but raising gross margin guidance to 73-75%. Despite facing commercial headwinds, RxSight highlighted its product pipeline, including next-generation LAL lenses, and its collaboration with Alcon for Presbyopia-Correcting Intraocular Lenses.

RxSight, Inc. announced its plans to participate in the upcoming Stifel 2026 Virtual Ophthalmology Forum. Management is scheduled to host a fireside chat on Tuesday, May 26, 2026, at 10:00 a.m. Pacific Time. A live and archived webcast of the presentation will be available on the company's investor relations website.

RxSight reported a significant decline in sales for Q1 2026, with revenue falling 18.5% to $30.9 million compared to the prior year. The company's net loss widened to $15.9 million, or $(0.38) per share, from a net loss of $8.2 million, or $(0.20) per share, in Q1 2025. Operating expenses increased, contributing to the larger loss. Despite the losses, RxSight believes its existing cash resources of $217.9 million are sufficient for at least the next 12 months.

RxSight, Inc. reported first-quarter 2026 sales of $30.9 million, an 18.5% decrease year-over-year, largely due to lower Light Delivery Device (LDD) unit volumes. The company posted a net loss of $(15.9) million, or $(0.38) per share, compared to a net loss of $(8.2) million in Q1 2025. Despite the sales decline, gross profit margin improved to 76.1%, driven by a favorable product mix. RxSight maintained its 2026 sales and gross margin guidance but expects operating expenses to be at the high end of the previous range due to strategic growth investments.

RxSight, Inc. announced its plan to participate in the upcoming Bank of America Healthcare Conference. Management is scheduled to hold a fireside chat on Wednesday, May 13, 2026, at 3:00 p.m. Pacific Time. A live and archived webcast of the presentation will be accessible via the company's investor relations website.

RxSight, Inc. announced its 2026 Annual Meeting of Stockholders will be held virtually on Tuesday, June 16, 2026, at 8:00 a.m. Pacific Time. Stockholders of record as of April 21, 2026, are invited to attend, submit questions, and vote online. Key proposals include the election of three Class II directors, an advisory vote on executive compensation, and the ratification of Ernst & Young LLP as the independent registered public accounting firm for fiscal year 2026.

RxSight, Inc. announced it will release its first-quarter financial results for 2026 after the market closes on Wednesday, May 6, 2026. Management will host a conference call on the same day at 1:30 p.m. Pacific Time to discuss the results. Investors can access the call via dial-in or a live webcast on the company's investor relations website.